$7.15
1.01%
Downside
Day's Volatility :6.63%
Upside
5.67%
56.78%
Downside
52 Weeks Volatility :62.68%
Upside
13.65%
Period | Brainsway Ltd | Index (Russel 2000) |
---|---|---|
3 Months | 11.02% | 0.0% |
6 Months | 20.17% | 0.0% |
1 Year | 93.77% | 0.0% |
3 Years | -11.18% | -22.3% |
Market Capitalization | 124.7M |
Book Value | $1.43 |
Earnings Per Share (EPS) | 0.02 |
PE Ratio | 357.5 |
Wall Street Target Price | 12.4 |
Profit Margin | 1.67% |
Operating Margin TTM | 5.86% |
Return On Assets TTM | 0.73% |
Return On Equity TTM | 1.44% |
Revenue TTM | 36.4M |
Revenue Per Share TTM | 2.15 |
Quarterly Revenue Growth YOY | 27.800000000000004% |
Gross Profit TTM | 20.0M |
EBITDA | 1.8M |
Diluted Eps TTM | 0.02 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.06 |
EPS Estimate Next Year | 0.08 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.01 |
What analysts predicted
Upside of 73.43%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 16.4M | ↑ 47.12% |
Net Income | -6.5M | ↓ 8.15% |
Net Profit Margin | -39.51% | ↑ 23.78% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 23.1M | ↑ 40.89% |
Net Income | -10.3M | ↑ 59.41% |
Net Profit Margin | -44.71% | ↓ 5.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 22.1M | ↓ 4.52% |
Net Income | -5.4M | ↓ 47.86% |
Net Profit Margin | -24.41% | ↑ 20.3% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 29.7M | ↑ 34.46% |
Net Income | -6.5M | ↑ 20.0% |
Net Profit Margin | -21.79% | ↑ 2.62% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.2M | ↓ 8.36% |
Net Income | -13.3M | ↑ 106.58% |
Net Profit Margin | -49.12% | ↓ 27.33% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.8M | ↑ 16.96% |
Net Income | -4.2M | ↓ 68.56% |
Net Profit Margin | -13.2% | ↑ 35.92% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.6M | ↑ 9.81% |
Net Income | -2.4M | ↓ 37.13% |
Net Profit Margin | -36.69% | ↑ 27.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↑ 18.17% |
Net Income | -1.7M | ↓ 31.59% |
Net Profit Margin | -21.24% | ↑ 15.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.3M | ↑ 6.04% |
Net Income | -230.0K | ↓ 86.17% |
Net Profit Margin | -2.77% | ↑ 18.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.0M | ↑ 8.76% |
Net Income | 127.0K | ↓ 155.22% |
Net Profit Margin | 1.41% | ↑ 4.18% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 9.1M | ↑ 0.73% |
Net Income | 111.0K | ↓ 12.6% |
Net Profit Margin | 1.22% | ↓ 0.19% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.0M | ↑ 10.01% |
Net Income | 600.0K | ↑ 440.54% |
Net Profit Margin | 6.0% | ↑ 4.78% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 23.6M | ↓ 12.68% |
Total Liabilities | 16.7M | ↑ 16.36% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 38.7M | ↑ 64.12% |
Total Liabilities | 14.5M | ↓ 12.82% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 34.0M | ↓ 12.2% |
Total Liabilities | 14.4M | ↓ 0.96% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 75.7M | ↑ 122.67% |
Total Liabilities | 18.4M | ↑ 28.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 64.5M | ↓ 14.86% |
Total Liabilities | 19.1M | ↑ 3.65% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 63.0M | ↓ 2.33% |
Total Liabilities | 15.3M | ↓ 19.74% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.0M | ↓ 3.91% |
Total Liabilities | 19.0M | ↓ 0.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 59.2M | ↓ 4.37% |
Total Liabilities | 17.9M | ↓ 6.02% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 59.8M | ↑ 0.89% |
Total Liabilities | 18.6M | ↑ 3.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 63.0M | ↑ 5.35% |
Total Liabilities | 15.3M | ↓ 17.47% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 65.1M | ↑ 3.45% |
Total Liabilities | 17.3M | ↑ 13.0% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 65.6M | ↑ 0.75% |
Total Liabilities | 16.6M | ↓ 4.28% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.8M | ↑ 8.83% |
Investing Cash Flow | -1.1M | ↓ 53.65% |
Financing Cash Flow | -265.0K | ↓ 102.39% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.2M | ↑ 92.0% |
Investing Cash Flow | -2.4M | ↑ 115.32% |
Financing Cash Flow | 22.5M | ↓ 8580.75% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.4M | ↓ 80.18% |
Investing Cash Flow | -2.5M | ↑ 0.78% |
Financing Cash Flow | -1.0M | ↓ 104.58% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 884.0K | ↓ 161.56% |
Investing Cash Flow | -42.2M | ↑ 1612.62% |
Financing Cash Flow | 41.5M | ↓ 4130.68% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.8M | ↓ 1203.96% |
Investing Cash Flow | 42.2M | ↓ 199.89% |
Financing Cash Flow | -1.5M | ↓ 103.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.5M | ↑ 57.94% |
Investing Cash Flow | 64.0K | ↓ 85.01% |
Financing Cash Flow | -66.0K | ↓ 9.59% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 995.0K | ↓ 128.1% |
Investing Cash Flow | -1.5M | ↓ 2460.94% |
Financing Cash Flow | -377.0K | ↑ 471.21% |
Sell
Neutral
Buy
Brainsway Ltd is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Brainsway Ltd | 4.84% | 20.17% | 93.77% | -11.18% | -31.9% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Brainsway Ltd | 357.5 | 357.5 | NA | 0.06 | 0.01 | 0.01 | NA | 1.43 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Brainsway Ltd | Buy | $124.7M | -31.9% | 357.5 | 1.67% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Brainsway Ltd
Revenue is up for the last 8 quarters, 5.16M → 10.00M (in $), with an average increase of 8.9% per quarter
Netprofit is up for the last 2 quarters, 111.0K → 600.0K (in $), with an average increase of 81.5% per quarter
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 92.1%
Masters Capital Management LLC
Phoenix Financial Ltd
Essex Investment Management Company, LLC
Dafna Capital Management LLC
Renaissance Technologies Corp
Acadian Asset Management LLC
brainsway is a leading global neurmodulation company with headquarters in jerusalem and the us. our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. a non-invasive, yet highly effective solution for brain disorders, brainsway has helped thousands of patients across the world, from the unites states to europe to south america, and has the potential to make a difference in the well-being and health of millions of patients worldwide. brainsway's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. brainsway's treatment has fda approval for treating patients with major depressive disorder*. the technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. in addition to being used to treat depression daily
Organization | Brainsway Ltd |
Employees | 134 |
CEO | Mr. Hadar Levy |
Industry | Medical Specialties |
A Spac I Acquisition Corp
$7.15
-2.99%
Keyarch Acquisition Corp
$7.15
-2.99%
Connexa Sports Technologies Inc
$7.15
-2.99%
Us Value Etf
$7.15
-2.99%
First Wave Biopharma Inc
$7.15
-2.99%
Global X Msci Next Emerging
$7.15
-2.99%
Fat Projects Acquisition Corp
$7.15
-2.99%
Capital Link Global Fintech
$7.15
-2.99%
Applied Uv Inc
$7.15
-2.99%